Brepocitinib is named as an intervention in 2 current clinical trials in our USA, UK, Canada and Australia registers. 2 are recruiting patients now. All registered phases are Phase 2/3. The lead sponsor is Priovant Therapeutics, Inc. The most-studied condition is Lichen Planopilaris.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
NCT06978725 · ClinicalTrials.gov ↗ · Cutaneous Sarcoidosis
|
Phase 2/3 | Recruiting | Priovant Therapeutics, Inc | USA |
|
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
NCT07532603 · ClinicalTrials.gov ↗ · Lichen Planopilaris
|
Phase 2/3 | Recruiting | Priovant Therapeutics, Inc | UK, USA, Canada, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
No entry for Brepocitinib in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Priovant Therapeutics, Inc | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Australia | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, UK, Canada and Australia registers name Brepocitinib as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 1 with sites in UK, 1 with sites in Canada and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Priovant Therapeutics, Inc. The number in brackets is how many trials each organisation leads.
Not in the lists we track: Brepocitinib has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Brepocitinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Brepocitinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Brepocitinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.